[18F]-AzaFol

[18F]-AzaFol is a diagnostic radiopharmaceutical used as a PET imaging agent targeting the folate receptor, particularly folate receptor alpha (FRα) and beta (FRβ). It is a fluorine-18 labeled folic acid analogue designed to bind with high affinity to cells expressing the folate receptor, which are overexpressed in various cancers and activated macrophages. The compound enables non-invasive visualization of tumors or inflammatory processes via positron emission tomography (PET). Developed initially by Itm Isotope Technologies Munich SE, [18F]-AzaFol has shown favorable dosimetric properties and safety in early clinical studies. Its primary indications include imaging of neoplasms such as lung adenocarcinoma and ovarian cancer, as well as potential use in large vessel vasculitis and other diseases characterized by increased expression of the folate receptor[1][2][5][6].

Other names

3′-Aza-2′-[18F]-fluoro-folic acid18F-AzaFol